Market closed
Avadel Pharmaceuticals/$AVDL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Avadel Pharmaceuticals
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Ticker
$AVDL
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
154
Website
AVDL Metrics
BasicAdvanced
$1.5B
Market cap
-
P/E ratio
-$1.16
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
52-week high
$19.09
52-week low
$12.16
Average daily volume
881K
Financial strength
Current ratio
2.819
Quick ratio
2.369
Long term debt to equity
52.357
Total debt to equity
53.59
Interest coverage (TTM)
-10.25%
Management effectiveness
Return on assets (TTM)
-34.44%
Return on equity (TTM)
-99.52%
Valuation
Price to revenue (TTM)
15.172
Price to book
21.52
Price to tangible book (TTM)
28.29
Price to free cash flow (TTM)
-12.647
Growth
Revenue change (TTM)
6,260.23%
Earnings per share change (TTM)
-46.73%
3-year earnings per share growth (CAGR)
2.92%
What the Analysts think about AVDL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Avadel Pharmaceuticals stock.
AVDL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AVDL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AVDL News
AllArticlesVideos
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
GlobeNewsWire·1 week ago
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
GlobeNewsWire·3 weeks ago
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Avadel Pharmaceuticals stock?
Avadel Pharmaceuticals (AVDL) has a market cap of $1.5B as of November 09, 2024.
What is the P/E ratio for Avadel Pharmaceuticals stock?
The price to earnings (P/E) ratio for Avadel Pharmaceuticals (AVDL) stock is 0 as of November 09, 2024.
Does Avadel Pharmaceuticals stock pay dividends?
No, Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders as of November 09, 2024.
When is the next Avadel Pharmaceuticals dividend payment date?
Avadel Pharmaceuticals (AVDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Avadel Pharmaceuticals?
Avadel Pharmaceuticals (AVDL) does not currently have a Beta indicator.